Pulvirenti L, Balducci C, Piercy M, Koob G F
Department of Neuropharmacology, The Scripps Research Institute, La Jolla, California, USA.
J Pharmacol Exp Ther. 1998 Sep;286(3):1231-8.
Dopamine neurotransmission is an important neuropharmacological component of cocaine self-administration in rodents. Terguride is a prototype drug belonging to a recently characterized class of compounds, dopamine partial agonists, which appear to possess a unique pharmacological profile in altering dopamine neurotransmission, where these drugs act as antagonists in conditions of high dopaminergic tone. The aim of the present study was therefore to test the effects of systemic administration of terguride in rats self-administering cocaine intravenously. The different aspects of cocaine self-administration examined after treatment with terguride were (a) the acute reinforcing properties of cocaine in rats exposed to limited-access self-administration of cocaine, (b) a full cocaine dose-effect function, (c) the reinforcing properties of cocaine as measured by a progressive ratio schedule and (d) the ability of terguride to maintain self-administration by itself. Terguride (0.025-0.4 mg/kg i.p.) significantly and dose-dependently reduced the acute reinforcing properties of cocaine as measured by an increase in responding for a single training dose of cocaine and a reduction of the inter-reinforcement interval. In addition, terguride (0.2-0.4 mg/kg) shifted the entire cocaine dose-effect function to the right, thus showing an antagonism of the reinforcing properties of cocaine independent of response rate. Moreover, in rats trained to self-administer cocaine on a progressive ratio schedule, terguride reduced the maximum fixed ratio ("breaking point") for cocaine reinforcement, also suggesting a decrease in the reinforcing properties of cocaine. Finally, in rats trained to self-administer cocaine terguride did not substitute for cocaine, thus indicating that terguride does not maintain intravenous self-administration by itself.
多巴胺神经传递是啮齿动物中可卡因自我给药的重要神经药理学组成部分。特麦角脲是一种原型药物,属于最近鉴定出的一类化合物,即多巴胺部分激动剂,这类药物在改变多巴胺神经传递方面似乎具有独特的药理学特征,在高多巴胺能张力条件下这些药物起拮抗剂作用。因此,本研究的目的是测试全身给予特麦角脲对静脉注射可卡因的大鼠的影响。在用特麦角脲治疗后检测可卡因自我给药的不同方面包括:(a)接触有限剂量可卡因自我给药的大鼠中可卡因的急性强化特性;(b)完整的可卡因剂量效应函数;(c)通过累进比率程序测量的可卡因强化特性;(d)特麦角脲自身维持自我给药的能力。特麦角脲(0.025 - 0.4毫克/千克,腹腔注射)显著且剂量依赖性地降低了可卡因的急性强化特性,这通过对单次训练剂量可卡因的反应增加和强化间隔的缩短来衡量。此外,特麦角脲(0.2 - 0.4毫克/千克)使整个可卡因剂量效应函数向右移动,从而显示出对可卡因强化特性的拮抗作用,且与反应率无关。此外,在按累进比率程序训练以自我给药可卡因的大鼠中,特麦角脲降低了可卡因强化的最大固定比率(“断点”),这也表明可卡因的强化特性降低。最后,在训练以自我给药可卡因的大鼠中,特麦角脲不能替代可卡因,因此表明特麦角脲自身不能维持静脉自我给药。